| |
Statin non-user
|
Statin user
|
p
|
ASD
|
|---|
|
N
|
25,764
|
25,764
| | |
|
Age group
| | |
1.0000
|
0.00000
|
|
40–49
|
3095 (12.01%)
|
3095 (12.01%)
| | |
|
50–59
|
9485 (36.81%)
|
9485 (36.81%)
| | |
|
60–69
|
7469 (28.99%)
|
7469 (28.99%)
| | |
|
70–79
|
4462 (17.32%)
|
4462 (17.32%)
| | |
|
> =80
|
1253 (4.86%)
|
1253 (4.86%)
| | |
|
Sex
| | |
1.0000
|
0.00000
|
|
Male
|
7298 (28.33%)
|
7298 (28.33%)
| | |
|
Female
|
18,466 (71.67%)
|
18,466 (71.67%)
| | |
|
Co-morbidities
|
|
Ischemic heart disease
|
6668 (25.88%)
|
8563 (33.24%)
|
<.0001
|
0.16184
|
|
Hypertension
|
13,454 (52.22%)
|
17,055 (66.20%)
|
<.0001
|
0.28735
|
|
Ischemic stroke
|
3298 (12.80%)
|
4531 (17.59%)
|
<.0001
|
0.13367
|
|
Diabetes mellitus
|
7250 (28.14%)
|
10,236 (39.73%)
|
<.0001
|
0.24653
|
|
Peptic ulcer
|
12,575 (48.81%)
|
12,110 (47.00%)
|
<.0001
|
−0.03624
|
|
Co-medication
|
|
Aspirin
|
3035 (11.78%)
|
6587 (25.57%)
|
<.0001
|
0.35953
|
|
Beta- blockers
|
5439 (21.11%)
|
8076 (31.35%)
|
<.0001
|
0.23440
|
|
CCBs
|
6820 (26.47%)
|
9939 (38.58%)
|
<.0001
|
0.26060
|
|
ACEI
|
2035 (7.90%)
|
3607 (14.00%)
|
<.0001
|
0.19625
|
|
ARBs
|
4060 (15.76%)
|
7321 (28.42%)
|
<.0001
|
0.30876
|
|
Duration of RA (year)
| | |
1.0000
|
0.00000
|
|
< 1
|
5402 (20.97%)
|
5402 (20.97%)
| | |
|
1–3
|
8018 (31.12%)
|
8018 (31.12%)
| | |
|
> 3
|
12,344 (47.91%)
|
12,344 (47.91%)
| | |
- ASD absolutely standardized difference, CCBs calicum channel blockers, ACEI angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers
